Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing safety, tolerability, and pharmacokinetics of lumateperone long-acting injectable formulations in people with schizophrenia or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Lumateperone long-acting injectable (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Schizophrenia or Schizoaffective | Phase 1 | Status: COMPLETED